durvalumab,ipilimumab,nivolumab
astrazeneca,orpathys,bms
['nivo', 'import', 'calypso', 'ipi/', 'rcc,(-irccs),(-srcc),(-urcc)']
calypso: data on targeting met in ccrcc is sparse, but it doesn t seem a great even in selected patients. there are not many randomised trials exploring pd(l)1 +/- ctla4. calypo raises some here questions despite shortcomings ++. 8y8 nivo vs ipi/nivo is important #asco22 
Interested in Urology Cancers, biomarkers and drug development.